Notices. Notice
1,171 words·~5 min read·
/register/2010/08/02/2010-18851·A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
BILLING CODE 4162-20-P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA-2010-N-0066] Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Human Tissue Intended for Transplantation AGENCY: Food and Drug Administration, HHS. ACTION: Notice. SUMMARY: The Food and Drug Administration
(FDA)is announcing that a proposed collection of information has been submitted to the Office of Management and Budget
(OMB)for review and clearance under the Paperwork Reduction Act of 1995. DATES: Fax written comments on the collection of information by [ *September 1, 2010.* ]. ADDRESSES: To ensure that comments on the information collection are received, OMB recommends that written comments be faxed to the Office of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer, FAX: 202-395-7285, or e-mailed to *oira_submission@omb.eop.gov* . All comments should be identified with the OMB control number 0910-0302. Also include the FDA docket number found in brackets in the heading of this document. FOR FURTHER INFORMATION CONTACT: Elizabeth Berbakos, Office of Information Management, Food and Drug Administration, 1350 Piccard Dr., PI50-400B, Rockville, MD 20850, 301-796-3792, *Elizabeth.Berbakos@fda.hhs.gov.* SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance. Human Tissue Intended for Transplantation—(OMB Control Number 0910-0302)—Extension Under section 361 of the Public Health Service
(PHS)Act (42 U.S.C. 264), FDA issued regulations under part 1270 (21 CFR part 1270) to prevent the transmission of human immunodeficiency virus (HIV), hepatitis B, and hepatitis C, through the use of human tissue for transplantation. The regulations provide for inspection by FDA of persons and tissue establishments engaged in the recovery, screening, testing, processing, storage, or distribution of human tissue. These facilities are required to meet provisions intended to ensure appropriate screening and testing of human tissue donors and to ensure that records are kept documenting that the appropriate screening and testing have been completed. Section 1270.31(a) through
(d)requires written procedures to be prepared and followed for the following steps:
(1)All significant steps in the infectious disease testing process under § 1270.21;
(2)all significant steps for obtaining, reviewing, and assessing the relevant medical records of the donor as prescribed in § 1270.21;
(3)designating and identifying quarantined tissue; and
(4)for prevention of infectious disease contamination or cross-contamination by tissue during processing. Section 1270.31(a) and
(b)also requires recording and justification of any deviation from the written procedures. Section 1270.33(a) requires records to be maintained concurrently with the performance of each significant step in the performance of infectious disease screening and testing of human tissue donors. Section 1270.33(f) requires records to be retained regarding the determination of the suitability of the donors and such records required under § 1270.21. Section 1270.33(h) requires all records to be retained at least 10 years beyond the date of transplantation if known, distribution, disposition, or expiration of the tissue, whichever is the latest. Section 1270.35(a) through
(d)requires specific records to be maintained to document the following:
(1)The results and interpretation of all required infectious disease tests;
(2)information on the identity and relevant medical records of the donor;
(3)the receipt and/or distribution of human tissue, and
(4)the destruction or other disposition of human tissue. Respondents to this collection of information are manufacturers of human tissue intended for transplantation. Based on information from the Center for Biologics Evaluation and Research's (CBER's) database system, FDA estimates that there are approximately 257 tissue establishments of which 145 are conventional tissue banks and 112 are eye tissue banks. Based on information provided by industry, there are an estimated total of 1,959,270 conventional tissue products and 82,741 eye tissue products recovered per year with an average of 25% of the tissue discarded due to unsuitability for transplant. In addition, there are an estimated 57,275 donors of conventional tissue and 54,115 donors of eye tissue each year. Accredited members of the American Association of Tissue Banks
(AATB)and Eye Bank Association of America
(EBAA)adhere to standards of those organizations that are comparable to the recordkeeping requirements in part 1270. Based on information provided by CBER's database system, 90% of the conventional tissue banks are members of AATB (145 x 90% = 130), and 77% of eye tissue banks are members of EBAA (112 x 77% = 86). Therefore, recordkeeping by these 216 establishments (130 + 86 = 216) is excluded from the burden estimates as usual and customary business activities (5 CFR 1320.3(b)(2)). The recordkeeping burden, thus, is estimated for the remaining 41 establishments, which is 16% of all establishments (257 - 216 = 41, or 41/257 = 16%). Based on CBER's database system and information provided by industry, FDA estimates an average of two new tissue banks annually, which may be non-members of a trade association. Each new tissue bank requires an estimated 64 hours to prepare standard operating procedures
(SOPs)under § 1270.31(a) through (d). The requirement for the development of these written procedures is considered an initial one-time burden. FDA assumes that all current tissue establishments have developed written procedures in compliance with part 1270. Therefore, their information collection burden is for the general review and update of written procedures estimated to take an annual average of 24 hours, and for the recording and justifying of any deviations from the written procedures for § 1270.31(a) and (b), estimated to take an annual average of 1 hour. The information collection burden for maintaining records concurrently with the performance of each significant screening and testing step and for retaining records for 10 years under § 1270.33(a), (f), and (h), include documenting the results and interpretation of all required infectious disease tests and results and the identity and relevant medical records of the donor required under § 1270.35(a) and (b). Therefore, the burden under these provisions is calculated together in table 1 of this document. The recordkeeping estimates for the number of total annual records and hours per record are based on information provided by industry and FDA experience. In the **Federal Register** of March 1, 2010 (75 FR 9226), FDA published a 60-day notice requesting public comment on the proposed collection of information. No comments were received on the information collection. FDA estimates the burden of this information collection as follows: **Table 2.—Estimated Annual Recordkeeping Burden** 1 21 CFR Section No. of Recordkeepers Annual Frequency per Recordkeeping Total Annual Records Hours per Record Total Hours 1270.31(a), (b), (c), and
(d)2 1 2 64 128 1270.31(a), (b), (c), and
(d)2 41 1 41 24 984 1270.31(a) and
(b)3 41 2 82 1 82 1270.33(a), (f), and (h), and 1270.35(a) and
(b)41 8,404 344,564 1 344,564 1270.35(c) 41 15,938 653,458 1 653,458 1270.35(d) 41 1,992 81,672 1 81,672 Total 1,080,888 1 There are no capital costs or operating and maintenance costs associated with this collection of information. 2 Review and update of SOPs. 3 Documentation of deviations from SOPs. Dated: July 27, 2010. Leslie Kux, Acting Assistant Commissioner for Policy. [FR Doc. 2010-18851 Filed 7-30-10; 8:45 am]
Connectionstraces to 2
2 references not yet in our index
- 21 CFR 1270
- 5 CFR 1320.3(b)(2)
Citation graph
cites case law
Cites 4Cited by 0 across 0 sources